EXHIBIT 3



CONTACT

The Immune Response Corporation

HOME | CORPORATE | NEWSROOM | INVESTOR RELATIONS | REMUNE | HIV/AIDS

newsroom

◁ BACK

June 7, 2004

The Immune Response Corporation Presents New Data on REMUNE® and IR103 Suggesting HIV-1 Specific Immune Responses
-- Preliminary Results from Ongoing Clinical Trial in Italy Suggest REMUNE® Has Activity in Drug-Naïve Patients --
-- Pre-Clinical Data Point to Potential of IR103 Combination to Boost this Effect --

Carlsbad, California – June 7, 2004 -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced that research results, presented Saturday at the International Symposium on HIV & Emerging Infectious Diseases in Toulon, France, suggest its lead product candidate, REMUNE® (HIV-1 immunogen), may produce an HIV-1 specific immune response in drug-naïve HIV-1 infected patients. The Company has also produced laboratory evidence that its second product candidate, IR103, which combines REMUNE® with an immunostimulatory oligonucleotide adjuvant Amplivax™, generated robust HIV-1 specific immune responses in a number of assays. Ability to generate HIV-1 specific immune responses is thought to be an important indicator of clinical utility. Additional studies are planned to investigate the clinical benefit of both products.

"These early clinical data from the Phase II trial in Italy represent further evidence that REMUNE® can generate the HIV-specific responses many investigators believe is necessary to be a useful therapeutic tool," said John N. Bonfiglio, Ph.D., Chief Executive Officer of The Immune Response Corporation. "The research models with Amplivax™ will help us plan our next stage of studies for IR103 which we hope to begin shortly. Moreover, this data demonstrates our continued progress toward our goal of achieving all of our published milestones."

In addition to preliminary results from an ongoing Phase II clinical trial, being conducted in Italy, in drug-naïve HIV-1 infected patients, the investigators presented findings from two research models that IR103, the combination of REMUNE® with Amplivax™, amplified HIV-1 specific immune activity over REMUNE® alone. On the basis of these encouraging laboratory results, the Company plans to evaluate the clinical potential of IR103 to enhance immune response by adding Amplivax™ to the REMUNE® vaccine patients in the ongoing study are currently receiving.

"It is encouraging to have evidence from two different models that the HIV-1 specific immune response can be enhanced with our IR103 product. Our clinical development plans for this year will generate more data in humans with IR103 in both drug-naïve patients and patients currently on antiretroviral therapy. These data will allow us to evaluate the clinical opportunities for both IR103 and REMUNE®," said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation.

In the preclinical model, mice immunized subcutaneously with IR103 showed significantly enhanced production of a number of key markers of HIV-specific immune responses, including gamma interferon (IFN-g) and important chemokines such as RANTES, MIP-1alpha, MIP-1beta and p24 antibody, when compared to those immunized with REMUNE® alone. These data demonstrate the potential to enhance both cell-mediated and humoral immunity, both of which are considered important in mounting an effective immune response against HIV.

In the ex-vivo study, AmplivaxTM was investigated for its ability to enhance HIV antigen stimulation from HIV+ patients treated with antiretroviral therapy (ART). Results showed that AmplivaxTM increased HIV-specific cell-mediated immune responses from patients vaccinated with REMUNE®, as measured primarily by IFN-g production.

Amplivax™ was developed by Hybridon, Inc. and has been licensed to The Immune Response Corporation.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company's HIV products are based on its patented whole-killed virus technology, co-invented by Company founder, Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. The Company has initiated development of a new IBT, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant.

The Immune Response Corporation is also developing an IBT for MS, NeuroVaxTM, which is currently in Phase II and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation on the World Wide Web at www.imnr.com
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVaxTM or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVaxTM or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVaxTM or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2003, and any subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation. NeuroVaxTM is a trademark of The Immune Response Corporation. Amplivax™ is a trademark of Hybridon, Inc.



CONTACT

The Immune Response Corporation

remune

◁ BACK

The Immune Response Corporation's REMUNE® is a therapeutic vaccine in development to treat individuals already infected by the human immunodeficiency virus (HIV). REMUNE is different from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual's immune system to attack HIV. The Company believes that results of previous clinical trials demonstrate that REMUNE boosts HIV-specific immune responses and has the potential to slow the progression of HIV infection when used alone or in conjunction with antiretroviral therapy. Furthermore, the Company believes that REMUNE stimulates the production of specific immune system modulators (cytokines and chemokines) that naturally protect components of the immune system from HIV infection.



Leading HIV clinical researchers have begun to recognize that in order to effectively stop or slow the progression of HIV to acquired immunodeficiency syndrome (AIDS), therapies must go beyond reducing viral load, as antiretroviral drugs do, to stimulate a sustained HIV-specific, cell-mediated immune response in infected individuals. For example, by using REMUNE in conjunction with existing antiretroviral drugs, it may be possible to boost the HIV-infected individual's immune system against the virus, prolonging and enhancing the effect of existing antiretroviral therapy.



CLICK HERE to watch a FLASH animation of how HIV interacts with the immune system.

[requires macromedia FLASH PLAYER]

Get macromedia FLASH PLAYER

Treatment of a patient with advanced AIDS in a hospital may cost as much as $100,000 annually. Currently, combination antiretroviral drugs, which cost about $20,000 per year and have numerous deleterious side effects, are the best available treatment for HIV disease. This has translated into a worldwide HIV market of $5

REMUNE

Data Suggest REMUNE®

- Boosts HIV-specil
- Maintains T-cell C
- Induces Chemoki
- May Have Activity Controlling Viral L

Acceptable Safety Profil

- Administered to m 2,000 HIV-infecte in 18 clinical trials
- No material adver effects observed

Dosing

billion in 2000 and is expected to grow to $13 billion by 2007. A Frost and Sullivan (www.frost.com) report indicates that by 2005, HIV/AIDS drug revenues are expected to top $5 billion in the United States alone.

- Injections every 3